Letters to the Editor
Vol. 17 No. 1 (2025): Review Articles, Original Article, Scientific Letter, Case Reports Letter to the Editor
Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: April 2, 2025
Accepted: May 22, 2025
Accepted: May 22, 2025
595
Views
474
Downloads
15
HTML
Authors
Downloads
Download data is not yet available.
Citations
How to Cite
“Efficacy and safety of teclistamab followed by autologous stem cells transplant in functional high-risk and triple class refractory multiple myeloma” (2025) Mediterranean Journal of Hematology and Infectious Diseases, 17(1), p. e2025051. doi:10.4084/MJHID.2025.051.
Copyright (c) 2025 Vincenzo Sammartano, Sara Ciofini, Beatrice Esposito Vangone, Chiara Carrara, Monica Bocchia, Alessandro Gozzetti
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
